72
Views
1
CrossRef citations to date
0
Altmetric
Letter

Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study – how useful is the current clinical gold standard for fracture risk?

, &
Pages 1653-1655 | Published online: 19 Oct 2015

Dear editor

Further to the recent publication on the “Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study”,Citation1 current data highlight the limitations of dual-energy X-ray absorptiometry scans. In this context, at best, dual-energy X-ray absorptiometry scans (which measure bone mineral density) can account for no greater than 50% of overall bone strength (defined as the ability to resist fracture). This is because the resulting images are two-dimensional and therefore unable to capture skeletal micro-architecture, which also contributes to bone strength.Citation2

A better clinical measure of overall bone strength that more accurately reflects the ability of that bone to resist fracture and hence fracture risk reflect an unmet need and is urgently required. Recent evidence suggests that micro-computed tomography scans, which enable three-dimensional imaging, might provide a solution but use so far has necessarily been limited to ex vivo assessment owing to radiation hazards as well as technical and accessibility issues.Citation3,Citation4 However micro-computed tomography images have identified bone volume fraction (the volumetric distribution of bone mass) as a strong determinant of bone strength (r2>0.8).Citation5,Citation6

Further, perhaps other potential tools, alone or in combination with imaging may also play a role. For example, serum biomarkers of bone metabolismCitation7,Citation8 along with other imaging modalities such as magnetic resonance imaging could capture the complex factors that make up bone strength.Citation9 Preexisting algorithms like the FRAX (a fracture risk assessment tool calculator)Citation10 might help reduce the overprediction issue currently faced.

With regard to the aforementioned evidence, there is a pressing need to consider first how we use bone densitometry in the diagnosis of osteoporosis in prostate cancer patients, before the National Health Service itself becomes fractured.

Disclosure

The authors report no conflicts of interest in this communication.

Authors’ replyCorrespondence: Po-Chou Liliang, Department of Neurosurgery, E-Da Hospital, I-Shou University, 1 Yi-Da Road, Yan-Chau Shiang, Kaohsiung City 824, Taiwan, Tel +866 7 615 0011, Fax +866 7 615 0982, Email [email protected]

Dear editor

We thank the authors for their interest and comments regarding our article.Citation1 The diagnosis of osteoporosis can be made using conventional radiography and by measuring the bone mineral density (BMD).Citation2 The most popular method of measuring BMD is dual-energy X-ray absorptiometry (DEXA) scans. DEXA scan is currently recommended by the World Health Organization; however, it maybe not a gold standard. The accuracy of this density estimate is affected by many factors. For example, smaller people with smaller bones will lower the scores, machines from different manufacturers use different algorithms and yield noncomparable results, and anatomic abnormalities, such as previous spine surgery or compression fractures, will also skew the measurement. DEXA calculates BMD using an area; it is not an accurate measurement of true BMD, which is mass divided by a volume. It is unable to represent the skeletal micro-architecture, which also contributes to bone strength.Citation3 In one study, some other technologies such as peripheral quantitative computed tomography and micro-computed tomography were able to improve the ability to assess structural parameters of cancellous and cortical bone.Citation4

Recently, some progress has been made in measuring biomarkers of bone metabolism. Biomarkers of bone metabolism are broadly divided into two categories:Citation5 markers of bone resorption, which reflect osteoclast activity and are for the most part degradation products of type I collagen; markers of bone formation, which reflect osteoblast activity and are byproducts of collagen synthesis, matrix proteins, or osteoblastic enzymes. These biomarkers can be easily measured in serum or urine.

Biomarkers of bone resorption are significantly elevated in postmenopausal women with osteoporosis, but the biomarkers of bone formation are not elevated and may indeed be decreased.Citation6,Citation7 Biomarkers seem to be promising for prediction of bone loss, fracture, and response to therapy. However, their use alone to predict fracture and for osteoporosis diagnosis has yet to be established.Citation8

Disclosure

The authors report no conflicts of interest in this communication.

References

  • LiangCLWangHKSyuFKWangKWLuKLiliangPCRepeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort studyClin Interv Aging20151063564225848240
  • GuglielmiGScalzoGImaging tools transform diagnosis of osteoporosisDiagnostic Imaging Europe2010263711
  • GreenspanSLWagnerJNelsonJBPereraSBrittonCResnickNMVertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapyJ Bone Miner Res201328232533222991066
  • BagiCMHansonNAndresenCThe use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXABone200638113614416301011
  • EastellRHannonRABiomarkers of bone health and osteoporosis riskProc Nutr Soc200867215716218412989
  • ValimakiMJTahtelaRJonesJDPetersonJMRiggsBLBone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-linksEur J Endocrinol199413132582627921210
  • KushidaKTakahashiMKawanaKInoueTComparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patientsJ Clin Endocrinol Metab19958084472450
  • GarneroPSornay-RenduEClaustratBDelmasPDBiochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY studyJ Bone Miner Res20001581526153610934651